StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7081.KL$0.26+4.00%
Fair $0.26+0.0%

7081.KL

Pharmaniaga Berhad

Healthcare / Medical DistributionKuala Lumpur

$0.26

+0.01 (+4.00%)

Fairly Valued+0.0%Fair Value $0.26Fund rank 22/100 · Data gapFallback financials|
SA 29/D
F-Score: 1/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-26.7M · quality 28.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 7081.KLLocal privado en este navegador · Pharmaniaga Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.7B

P/E

26.0x

↑

EV/EBITDA

11.0x

↓

ROE

11.2%

↑

Gross Margin

10.4%

↓

Debt/Equity

1.89

↑
52-Week Range$0
$0$0

TradingView lightweight chart

7081.KL price, volumen y niveles de valoración

Último $0.260Periodo -45.3%
Fair value: $0.260

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+4.1%

FCF CAGR

—

FCF margin

-1.4%

FCF / Net income

-1.16x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.93B · net income $48.5M · FCF $-56.4M

2022-FY → 2025-FY

Gross margin

10.4%+16.4% pts

Operating margin

3.3%+18.4% pts

Net margin

1.2%+19.3% pts

FCF margin

-1.4%+4.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.93B$3.93B$3.76B$3.40B$3.48B
Net Income$48.5M$48.5M$131.8M$-80.2M$-629.9M
EBITDA$136.1M$136.1M$266.1M$-16.3M$-570.5M
EPS0.010.010.05-0.03-0.29
Gross Margin10.4%10.4%14.4%9.0%-6.0%
Operating Margin3.3%3.3%6.9%-0.6%-15.1%
Net Margin1.2%1.2%3.5%-2.4%-18.1%
Balance Sheet
Debt/Equity1.891.89-6.96-3.98-3.16
Current Ratio0.920.92———
Cash Flow
Free Cash Flow$-56.4M$-56.4M$3.1M$-26.7M$-220.0M
Returns
ROE11.2%11.2%-77.0%26.8%170.4%
Valuation
P/E26.0026.006.34——
EV/EBITDA11.0311.037.12——
P/B2.162.16———
Growth & Yield
Revenue Growth4.5%4.5%10.4%-2.2%—
EPS Growth-75.4%-75.4%256.1%87.8%—
Dividend Yield1.0%1.0%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

19.9%

exigente

EPS terminal req.

$0.02

Spread vs growth

-95.2%

5Y implied EPS CAGR

15.8%

exigente

EPS terminal req.

$0.03

Spread vs growth

-91.2%

10Y implied EPS CAGR

12.9%

razonable

EPS terminal req.

$0.04

Spread vs growth

-88.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.2%

Total return

-6.2%

Start / end P/E

5.1x → 19.4x

EPS bridge

0.05 → 0.01

Residual

-208.7%

EPS growth-75.4%
Multiple rerating+276.9%
Dividend+1.0%
Residual / FX / buybacks / cross-term-208.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.